How sponsors keep patient enrollment moving and avoid ocular assessment bottlenecks When recruitment outpaces assessment capacity, timelines slip, and qualified participants disengage. Traditional,...
Read More
In today’s funding environment, sponsors cannot afford preventable rework on ocular endpoints. Regulators are closely examining a potential link between GLP-1 receptor agonists and non-arteritic...
Read More
In today’s capital-constrained clinical landscape, every protocol deviation, rescreen, and unplanned patient visit translates into real financial and timeline risk. Ocular endpoints, such as BCVA,...
Read More
Legacy ophthalmic trial sites were built using traditional models. These solutions have done an admirable job and have advanced research exponentially, but as the industry continues to evolve,...
Read More
GLP-1 receptor agonists, such as semaglutide, have emerged as powerful therapeutic agents, transforming the management of type 2 diabetes, weight management, and cardiovascular health.
Read More
Imaging in clinical trials isn’t optional anymore; it’s foundational. In GLP-1 and neurology trials, where ocular endpoint sensitivity is everything, the quality and timing of imaging can directly...
Read More
At ARVO 2025, one truth cut through the noise: you can’t innovate at the expense of data integrity. As trials evolve to be more decentralized and patient-centric, the pressure to maintain precision,...
Read More
When planning a clinical trial, there's a tendency to focus on enrollment—building lists, recruiting participants, and getting sites up and running quickly. While this is important to hit deadlines...
Read More